You can buy or sell MRKR and other stocks, options, ETFs, and crypto commission-free!
Marker Therapeutics, Inc. Common Stock, also called Marker Therapeutics, is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Read More The company was founded on October 22, 1991 and is headquartered in Houston, TX.
52 Week High
52 Week Low
Yahoo FinanceMay 7
Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
HOUSTON, May 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will be presenting at the 2019 Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, 2019. Marker Therapeutics, Inc. (PRNewsfoto/Marker Therap...
Expected Aug 8, After Hours